Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report
Octreotide plus IBI318 plus anlotinib achieved benefits in a patient with advanced NETs of unknown primary lesions after first-line treatment failure, even though with low PD-L1 expression. This case suggests that combining SSAs, TKIs and PD-1/PD-L1 inhibitors could be an alternative second-line treatment for patients with advanced, well-differentiated NETs.
Authors
- Liang Zeng (ORCID: https://orcid.org/0000-0003-3860-7724)
- Haoyue Qin
- Xing Zhang (ORCID: https://orcid.org/0000-0001-8542-8353)
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Zhe Huang (ORCID: https://orcid.org/0000-0002-9201-9491)
- Huan Yan (ORCID: https://orcid.org/0000-0001-7546-8087)
- Yuda Zhang
- Yangqian Chen
- Siqi Xiang
- Nong Yang
Institutions
- Central South University (CN)
- Hunan University (CN)
- Hunan Cancer Hospital (CN)
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fonc.2024.1390299
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- National Natural Science Foundation of China